Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Univariate analyses of the interval and other covariates based on Cox regression model

From: The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma

Factors OS DFS DMFS LRFS
HR (95% CI) P* HR (95% CI) P* HR (95% CI) P* HR (95% CI) P*
Interval between IC and RT (>  30 vs. ≤ 30 days) 2.43 (1.49–3.95) < 0.001 1.90 (1.22–2.95) 0.005 2.67 (1.57–4.53) < 0.001 1.57 (0.78–3.16) 0.208
Age (continuous) 1.02 (1.01–1.04) 0.010 1.02 (1.00–1.03) 0.040 1.00 (0.98–1.02) 0.899 1.01 (0.99–1.03) 0.240
Sex (Female vs. Male) 0.85 (0.54–1.34) 0.487 1.00 (0.69–1.43) 0.985 1.04 (0.65–1.67) 0.866 1.24 (0.74–2.07) 0.425
T category (T3–4 vs. T1–2) 1.45 (0.87–2.41) 0.149 1.28 (0.86–1.92) 0.228 1.15 (0.68–1.92) 0.608 1.54 (0.81–2.92) 0.192
N category (N2–3 vs. N0–1) 2.22 (1.52–3.24) < 0.001 1.66 (1.21–2.28) 0.002 3.17 (2.08–4.85) < 0.001 0.82 (0.49–1.38) 0.464
lnDNA (continuous) 1.06 (1.01–1.12) 0.022 1.07 (1.02–1.12) 0.004 1.17 (1.09–1.26) < 0.001 1.04 (0.98–1.11) 0.187
WHO pathology (III vs. I/II) 0.59 (0.30–1.18) 0.135 0.75 (0.41–1.39) 0.361 1.25 (0.46–3.41) 0.661 0.43 (0.21–0.90) 0.025
CCI (≥ 1 vs. 0) 2.03 (1.29–3.21) 0.002 1.74 (1.18–2.57) 0.005 1.22 (0.69–2.16) 0.496 1.38 (0.74–2.58) 0.310
IC cycles (>  2 vs. ≤ 2) 1.29 (0.88–1.89) 0.187 1.25 (0.91–1.71) 0.170 1.39 (0.92–2.12) 0.118 1.26 (0.79–2.03) 0.336
Concurrent chemotherapy (Yes vs. No) 0.97 (0.60–1.56) 0.903 0.99 (0.67–1.46) 0.946 1.10 (0.64–1.89) 0.728 1.05 (0.58–1.92) 0.869
  1. Abbreviations: OS Overall survival, DFS Disease-free survival, DMFS Distant metastasis-free survival, LRFS Locoregional recurrence-free survival, HR Hazard ratio, CI Confidence interval, IC Induction chemotherapy, RT Radiotherapy, CCI Charlson comorbidity index
  2. *Wald chi-square test